
Molecular Partners AG
SIX:MOLN


to continue MOLN research
to continue MOLN research
You've reached your weekly stock limit.
Sign UpMolecular Partners AG?
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
Retail
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
Energy
|
We'll email you a reminder when the closing price reaches USD.
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.865
9.3
|
Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.

What unique competitive advantages
does Molecular Partners AG hold over its rivals?
What risks and challenges
does Molecular Partners AG face in the near future?
Is it considered overvalued or undervalued
based on the latest financial data?
Provide an overview of the primary business activities
of Molecular Partners AG.
Provide an overview of the primary business activities
of Molecular Partners AG.
What unique competitive advantages
does Molecular Partners AG hold over its rivals?
What risks and challenges
does Molecular Partners AG face in the near future?
Has there been any significant insider trading activity
in Molecular Partners AG recently?
Summarize the latest earnings call
of Molecular Partners AG.
Is it considered overvalued or undervalued
based on the latest financial data?
Show all valuation multiples
for Molecular Partners AG.
Provide P/S
for Molecular Partners AG.
Provide P/E
for Molecular Partners AG.
Provide P/OCF
for Molecular Partners AG.
Provide P/FCFE
for Molecular Partners AG.
Provide P/B
for Molecular Partners AG.
Provide EV/S
for Molecular Partners AG.
Provide EV/GP
for Molecular Partners AG.
Provide EV/EBITDA
for Molecular Partners AG.
Provide EV/EBIT
for Molecular Partners AG.
Provide EV/OCF
for Molecular Partners AG.
Provide EV/FCFF
for Molecular Partners AG.
Provide EV/IC
for Molecular Partners AG.
Show me price targets
for Molecular Partners AG made by professional analysts.
What are the Revenue projections
for Molecular Partners AG?
How accurate were the past Revenue estimates
for Molecular Partners AG?
What are the Net Income projections
for Molecular Partners AG?
How accurate were the past Net Income estimates
for Molecular Partners AG?
What are the EPS projections
for Molecular Partners AG?
How accurate were the past EPS estimates
for Molecular Partners AG?
What are the EBIT projections
for Molecular Partners AG?
How accurate were the past EBIT estimates
for Molecular Partners AG?
Compare the revenue forecasts
for Molecular Partners AG with those of its competitors based on recent analyst estimates.
Compare the intrinsic valuations
of Molecular Partners AG and its key competitors using the latest financial data.
Compare historical revenue growth rates
of Molecular Partners AG against its competitors.
Analyze the profit margins
(gross, operating, and net) of Molecular Partners AG compared to its peers.
Compare the P/E ratios
of Molecular Partners AG against its peers.
Discuss the investment returns and shareholder value creation
comparing Molecular Partners AG with its peers.
Analyze the financial leverage
of Molecular Partners AG compared to its main competitors.
Show all profitability ratios
for Molecular Partners AG.
Provide ROE
for Molecular Partners AG.
Provide ROA
for Molecular Partners AG.
Provide ROIC
for Molecular Partners AG.
Provide ROCE
for Molecular Partners AG.
Provide Gross Margin
for Molecular Partners AG.
Provide Operating Margin
for Molecular Partners AG.
Provide Net Margin
for Molecular Partners AG.
Provide FCF Margin
for Molecular Partners AG.
Show all solvency ratios
for Molecular Partners AG.
Provide D/E Ratio
for Molecular Partners AG.
Provide D/A Ratio
for Molecular Partners AG.
Provide Interest Coverage Ratio
for Molecular Partners AG.
Provide Altman Z-Score Ratio
for Molecular Partners AG.
Provide Quick Ratio
for Molecular Partners AG.
Provide Current Ratio
for Molecular Partners AG.
Provide Cash Ratio
for Molecular Partners AG.
What is the historical Revenue growth
over the last 5 years for Molecular Partners AG?
What is the historical Net Income growth
over the last 5 years for Molecular Partners AG?
What is the current Free Cash Flow
of Molecular Partners AG?
Discuss the annual earnings per share (EPS)
trend over the past five years for Molecular Partners AG.
EV/EBIT
Enterprise Value to EBIT
Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.
Market Cap | EV/EBIT | ||||
---|---|---|---|---|---|
CH |
![]() |
Molecular Partners AG
SIX:MOLN
|
114.8m CHF | 0.5 | |
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
6T USD | -195 147.7 |
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
337.5B USD | 22.8 |
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
158.7B USD | 23.7 |
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
136.9B USD | 13.8 |
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117B USD | 26.4 |
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -557.1 |
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
115.7B AUD | 21.1 |
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
57.3B USD | 12.7 |
|
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -59.2 |
|
US |
![]() |
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
40.1B USD | -333.9 |
|
EBIT Growth | EV/EBIT to Growth | |||||
---|---|---|---|---|---|---|
CH |
![]() |
Molecular Partners AG
SIX:MOLN
|
Average EV/EBIT:
17.3
0.5
|
N/A | N/A | |
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
Negative Multiple: -195 147.7 | N/A | N/A |
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
22.8
|
29%
|
0.8 |
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
23.7
|
32%
|
0.7 |
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
13.8
|
11%
|
1.3 |
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
26.4
|
17%
|
1.6 |
|
US |
E
|
Epizyme Inc
F:EPE
|
Negative Multiple: -557.1 | N/A | N/A |
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
21.1
|
14%
|
1.5 |
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
12.7
|
11%
|
1.2 |
|
US |
S
|
Seagen Inc
F:SGT
|
Negative Multiple: -59.2 | N/A | N/A |
|
US |
![]() |
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Negative Multiple: -333.9 | N/A | N/A |
|
EV/EBIT Forward Multiples
Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.